Compare Stocks

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

iLOOKABOUT Corp., together with its subsidiaries, provides software and data licenses and technology managed services to the real estate industry in Canada and the United States. The company offers GeoViewPort, a web-based platform that enables assessment professionals to simultaneously generate customized portals to view multiple elements related to a property, including street level imagery, aerial imagery, advanced mapping tools, property valuation details, comparable property analysis, and structural characteristics. It also provides FusionOMSm, a web-based platform that enables real property valuation solutions to enterprises through US nationwide repository of public record and multiple listing service data; and Real Property Tax Analytics, a web-based platform that analyzes property assessments. In addition, the company offers data commercialization products and services through the delivery of reports and individual data requests to users through e-commerce transactions or by account, as well as customized reports through an assisted fulfillment process. Further, it provides valuation management and property tax solutions, which include assessment base management, analytics reports, tax policy planning and support, and appeals management. It primarily serves property lending and property tax sectors. iLOOKABOUT Corp. was founded in 2000 and is based in London, Canada.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.